---
title: "Obefazimod (ABX464) in Ulcerative colitis: ABTECT-2"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: ABTECT-2. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 49 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence/abtect-2"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: ABTECT-2

<a id="heading-3.1.2"></a>

## 3.1.2 ABTECT-2

<a id="heading-3.1.2.1"></a>

### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

#### Purpose stated in the ClinicalTrials.gov brief summary

> “This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies [corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)] and/or advanced therapies [biologics (TNF inhibitors, anti-integrins, anti-IL-23), and/or S1P receptor modulators, and/or JAK inhibitors].”

Source: [ClinicalTrials.gov NCT05507216](https://clinicaltrials.gov/study/NCT05507216)

<a id="topic-3.1.2.1-2"></a>

#### Primary objectives for the FDA and for the EMA in the protocol

> “For the FDA and National Regulatory Authorities other than EMA purposes, the primary efficacy objective is to compare the efficacy of obefazimod versus placebo on clinical remission defined as:”
> “For the EMA purposes, the primary efficacy objective is to compare the efficacy of obefazimod versus placebo on endoscopic improvement and symptomatic remission.”

Source: [Abivax ABX464-106 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/16/NCT05507216/Prot_000.pdf)

<a id="topic-3.1.2.1-3"></a>

#### Place of the trial in the phase 3 development plan

> “This study is part of a phase 3 clinical development program comprising two similar 8-week induction studies (ABX464-105 and ABX464-106), followed by a maintenance study (ABX464-107) to confirm the efficacy and safety of obefazimod in the short and long-term treatment of moderate to severely active UC in adults and adolescents from 16 to 18 years of age.”

Source: [Abivax ABX464-106 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/16/NCT05507216/Prot_000.pdf)

<a id="topic-3.1.2.1-4"></a>

#### Main objective in the EU Clinical Trials Information System record

> “Main objective To compare the efficacy of obefazimod versus placebo on endoscopic improvement and symptomatic remission.”

Source: [EU Clinical Trials Information System 2022-500536-11-01](https://euclinicaltrials.eu/ctis-public/view/2022-500536-11-01)

<a id="heading-3.1.2.2"></a>

### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

#### Study dates and status in the ClinicalTrials.gov record

> “Study Start (Actual) 2023-01-25”
> “Primary Completion (Actual) 2025-06-24”
> “Study Completion (Actual) 2025-07-15”
> “First Posted 2022-08-18”
> “Results First Posted 2026-09-10”
> “Last Update Posted 2026-09-10”

Source: [ClinicalTrials.gov NCT05507216](https://clinicaltrials.gov/study/NCT05507216)

<a id="topic-3.1.2.2-2"></a>

#### Number of locations in the ClinicalTrials.gov record

> “This study has 262 locations”

Source: [ClinicalTrials.gov NCT05507216](https://clinicaltrials.gov/study/NCT05507216)

<a id="topic-3.1.2.2-3"></a>

#### Planned number of sites and potential countries in the protocol

> “Approximately 350 sites located worldwide will participate in the study.”
> “(List of potential countries: Argentina, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Croatia, Czech Republic, France, Germany, Hungary, India, Ireland, Israel, Italy, Japan, Lithuania, Mexico, New Zealand, Poland, Romania, Serbia, Slovakia, Spain, UK, Ukraine, USA)”

Source: [Abivax ABX464-106 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/16/NCT05507216/Prot_000.pdf)

<a id="topic-3.1.2.2-4"></a>

#### EU member states and trial dates in the EU Clinical Trials Information System record

> “Locations Romania, Poland, Slovakia, Germany, Ireland, Lithuania, Italy, Croatia, Belgium, Bulgaria, France, Czechia, Hungary, Spain”
> “Start of trial 08/06/2023 End of trial 23/06/2025 Global end of trial 15/07/2025”

Source: [EU Clinical Trials Information System 2022-500536-11-01](https://euclinicaltrials.eu/ctis-public/view/2022-500536-11-01)

<a id="topic-3.1.2.2-5"></a>

#### Sites and countries of the two induction trials stated by the company

> “ABTECT-1 and ABTECT-2 were conducted simultaneously and have enrolled 1,275 patients from over 600 participating clinical trial sites in 36 countries with the intent to satisfy regulatory requirements globally.”

Source: [Abivax press release, ABTECT induction results (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-phase-3-results-both-abtect-8-week)

<a id="heading-3.1.2.3"></a>

### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

#### Design in the ClinicalTrials.gov record

> “Official Title A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of ABX464 Once Daily for Induction Treatment in Subjects With Moderately to Severely Active Ulcerative Colitis”
> “Allocation : Randomized”
> “Interventional Model : Parallel Assignment”
> “Masking : Triple”

Source: [ClinicalTrials.gov NCT05507216](https://clinicaltrials.gov/study/NCT05507216)

<a id="topic-3.1.2.3-2"></a>

#### Periods, randomization ratio, and planned arm sizes in the protocol

> “This induction study is a multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of obefazimod given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response (lack of response, loss of response, or intolerance) to either conventional therapies and/or advanced therapies.”
> “As shown below, this study consists of a screening period of up to 4 weeks, an 8-week induction period followed by 4-week follow up period.”
> “On Day 1, eligible subjects will be randomized and allocated into three treatment arms according to ratio 1:1:2 as follows: Placebo: 153 subjects Obefazimod Daily dose 25 mg QD: 153 subjects Obefazimod Daily dose 50 mg QD: 306 subjects”

Source: [Abivax ABX464-106 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/16/NCT05507216/Prot_000.pdf)

<a id="topic-3.1.2.3-3"></a>

#### Randomization stratification factors, including region

> “Randomization will be stratified according to the following factors: Subjects with inadequate response to advanced therapies [AT-IR subjects] (lack of response, loss of response or intolerance to advanced therapies (Yes/No) Subjects with concomitant oral corticosteroids at baseline (Yes/No) Region (Japan/Rest of world)”
> “Previous discontinuation of an advance therapy for any reason other than inadequate response, e.g., pregnancy, economic reasons or termination of a clinical trial, will not be considered as AT-IR.”

Source: [Abivax ABX464-106 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/16/NCT05507216/Prot_000.pdf)

<a id="topic-3.1.2.3-4"></a>

#### Endoscopy, central reading, and electronic diaries

> “Endoscopies will be centrally read.”
> “Biopsies will be centrally analyzed.”
> “e-Diaries will be used to collect stool frequency, rectal bleedings, nocturnal bowel movements, bowel urgency and fatigue NRS on a daily basis, as well as whether the subjects took the study treatment and the intake time.”

Source: [Abivax ABX464-106 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/16/NCT05507216/Prot_000.pdf)

<a id="topic-3.1.2.3-5"></a>

#### Entry into the maintenance trial after Week 8

> “In the randomized double-blind placebo-controlled study part [Part 1; placebo, obefazimod 25 mg, obefazimod 50 mg] for clinical responders at Week 8.”

Source: [Abivax ABX464-106 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/16/NCT05507216/Prot_000.pdf)

<a id="topic-3.1.2.3-6"></a>

#### Rationale for the 8-week treatment duration in the protocol

> “After 16 weeks of treatment there were a limited number of patients who achieved a clinical response that was not observed at Week 8. Therefore, it is reasonable to define 8 weeks as the treatment duration for the induction study.”

Source: [Abivax ABX464-106 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/16/NCT05507216/Prot_000.pdf)

<a id="heading-3.1.2.4"></a>

### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

#### Key inclusion criteria in the ClinicalTrials.gov record

> “Men or women at least 16 years old; Adolescent subjects will only be enrolled if approved by the country regulatory/health authority.”
> “To be eligible, adolescent subjects must weigh ≥ 40 kg and meet the definition of Tanner Stage 5 at the screening visit.”
> “Active disease defined by modified Mayo score (MMS) ≥ 5 with rectal bleeding subscore (RBS) ≥ 1 and endoscopy subscore (MES) of 2 or 3 (confirmed by central reader).”
> “Subjects with documented inadequate response (defined as lack of response or loss of response or intolerance) to at least one of the following treatments: corticosteroids, immunosuppressant, biologic or biosimilar therapies, S1P receptor modulators and/or JAK inhibitors and/or new drugs approved during the study (note: failure to only 5-ASA or sulfasalazine is not accepted).”

Source: [ClinicalTrials.gov NCT05507216](https://clinicaltrials.gov/study/NCT05507216)

<a id="topic-3.1.2.4-2"></a>

#### Key exclusion criteria in the ClinicalTrials.gov record

> “Subjects with UC limited to an isolated proctitis (≤ 15cm from anal verge) determined by endoscopy central reading.”
> “Subjects with primary sclerosing cholangitis or autoimmune hepatitis.”
> “Creatinine clearance < 60 mL.min-1 (Cockroft-Gault formula)”
> “Subjects with HIV infection.”
> “Subjects previously treated with ABX464.”

Source: [ClinicalTrials.gov NCT05507216](https://clinicaltrials.gov/study/NCT05507216)

<a id="topic-3.1.2.4-3"></a>

#### Minimum age by region in the protocol

> “Male or female (at birth) at least 16 years old, except in European Union (EU)/European Economic Area (EEA), Israel, Serbia and Ukraine, where subjects must be at least 18 years old at the time of eligibility assessment.”

Source: [Abivax ABX464-106 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/16/NCT05507216/Prot_000.pdf)

<a id="topic-3.1.2.4-4"></a>

#### Age range in the EU Clinical Trials Information System record

> “Age range 65+ years, 18-64 years”

Source: [EU Clinical Trials Information System 2022-500536-11-01](https://euclinicaltrials.eu/ctis-public/view/2022-500536-11-01)

<a id="topic-3.1.2.4-5"></a>

#### Eligibility summarized in the late-breaking abstract

> “The multicenter, randomized, double‐blind, placebo‐controlled ABTECT trials enrolled pts with moderate‐to‐severe UC (defined as modified Mayo score (MMS) ≥ 5, with rectal bleeding sub‐score (RBS) ≥ 1 and centrally read endoscopic score ≥ 2) who had inadequate response, loss of response, or intolerance to at least one prior therapy (with no upper limit), including corticosteroids, immunosuppressants, biologics, S1P receptor modulators and/or JAK inhibitors.”

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

<a id="heading-3.1.2.5"></a>

### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

#### Arms and administration in the ClinicalTrials.gov record

| Arm | Description in the record |
| --- | --- |
| ABX464 50 mg | “Experimental: ABX464 50mg Subjects will be orally dosed daily in a fed condition (ideally at the same time in the morning) for 8 weeks” |
| ABX464 25 mg | “Experimental: ABX464 25mg Subjects will be orally dosed daily in a fed condition (ideally at the same time in the morning) for 8 weeks” |
| Placebo | “Placebo Comparator: Placebo Subjects will be orally dosed daily in a fed condition (ideally at the same time in the morning) for 8 weeks” |
| Intervention | “Administered once daily in the morning with food” |

Source: [ClinicalTrials.gov NCT05507216](https://clinicaltrials.gov/study/NCT05507216)

<a id="topic-3.1.2.5-2"></a>

#### Capsule strengths and dosing instructions in the protocol

> “Depending on the treatment arm allocation, obefazimod or its matching placebo (capsules) 50 mg and 25 mg are administered once daily in a fed condition (ideally at the same time in the morning) for 8 weeks during the induction phase.”
> “25 mg regimen: 1 capsule of obefazimod 25 mg per day”
> “50 mg regimen: 1 capsule of obefazimod 50 mg per day”
> “1 capsule of placebo per day”

Source: [Abivax ABX464-106 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/16/NCT05507216/Prot_000.pdf)

<a id="topic-3.1.2.5-3"></a>

#### Background ulcerative colitis therapy allowed during the trial

> “For the treatment of UC (provided stable dose for at least 2 weeks prior to the screening endoscopy and during the whole induction study), the following medications are allowed upon entry into the study:”
> “Oral 5-ASA.”
> “At study entry, subjects randomized to any treatment group may continue certain background therapy for UC (e.g., 5-aminosalicylic acid [5-ASA] compounds and/or oral CS); therefore, even subjects randomized to the placebo treatment during the treatment period will have concomitant therapies that may be partially effective at controlling UC symptoms.”

Source: [Abivax ABX464-106 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/16/NCT05507216/Prot_000.pdf)

<a id="heading-3.1.2.6"></a>

### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

#### 3.1.2.6.1 Rationale for Using Clinical Remission by Modified Mayo Score as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

##### Primary endpoint and its definition in the ClinicalTrials.gov record

> “Proportion of Subjects Who Achieve Clinical Remission Per Modified Mayo Score at Week 8”
> “Clinical remission is defined as stool frequency subscore (SFS) = 0 or 1 and rectal bleeding subscore (RBS) = 0, and Mayo Endoscopic Score (MES) = 0 or 1 (MES of 1 modified to exclude friability).”

Source: [ClinicalTrials.gov NCT05507216](https://clinicaltrials.gov/study/NCT05507216)

<a id="topic-3.1.2.6.1-2"></a>

##### FDA recommendation of clinical remission by the modified Mayo Score as the primary endpoint

> “We recommend evaluating the proportion of subjects achieving clinical remission as the”
> “Clinical remission: Defined as an mMS score of 0 to 2, including the following three”
> “The previously used physician global assessment component is excluded to reduce subjectivity and focus the evaluation on the subject’s directly reported symptoms and directly observable endoscopic findings.”

Source: [FDA draft guidance, ulcerative colitis drug development (2022)](https://www.fda.gov/media/158016/download)

<a id="topic-3.1.2.6.1-3"></a>

##### Co-primary endpoints for the EMA and key secondary endpoints for the FDA

> “The co-primary endpoints are defined as: o Proportion of subjects who achieve endoscopic improvement at Week 8 o Proportion of subjects with symptomatic remission at Week 8.”
> “For the FDA and National Regulatory Authorities other than EMA, the key secondary efficacy objectives and endpoints are: To compare the efficacy of obefazimod versus placebo on endoscopic improvement. o Proportion of subjects who achieve endoscopic improvement at Week 8. To compare the efficacy of obefazimod versus placebo on clinical response o Proportion of subjects with clinical response at Week 8. To compare the efficacy of obefazimod versus placebo on HEMI.”

Source: [Abivax ABX464-106 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/16/NCT05507216/Prot_000.pdf)

<a id="topic-3.1.2.6.1-4"></a>

##### Secondary endpoint definitions in the ClinicalTrials.gov record

> “Clinical Response is defined as a reduction from baseline in MMS ≥ 2 points and a relative reduction from baseline in MMS ≥ 30%, and a reduction from baseline in Rectal Bleeding Score (RBS) ≥ 1 point and/or RBS = 0 or 1.”
> “HEMI is defined as endoscopic improvement associated with histologic improvement per Geboes score.”

Source: [ClinicalTrials.gov NCT05507216](https://clinicaltrials.gov/study/NCT05507216)

<a id="heading-3.1.2.7"></a>

### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

#### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

##### Planned sample size in the protocol

> “Approximately 612 subjects will be randomized in this study.”

Source: [Abivax ABX464-106 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/16/NCT05507216/Prot_000.pdf)

<a id="topic-3.1.2.7.1-2"></a>

##### Actual enrollment in the ClinicalTrials.gov record

> “Enrollment (Actual) 636”

Source: [ClinicalTrials.gov NCT05507216](https://clinicaltrials.gov/study/NCT05507216)

<a id="topic-3.1.2.7.1-3"></a>

##### Participants analyzed by arm in the posted results

| Population | ABX464 50 mg | ABX464 25 mg | Placebo | Total |
| --- | --- | --- | --- | --- |
| Started | “318” | “159” | “159” | Not reported |
| Baseline | “318” | “159” | “159” | “636” |
| Adverse events (at risk) | “0/318 (0.00%)” | “0/159 (0.00%)” | “0/159 (0.00%)” | Not reported |

Source: [ClinicalTrials.gov NCT05507216 results](https://clinicaltrials.gov/study/NCT05507216?tab=results)

<a id="topic-3.1.2.7.1-4"></a>

##### Participants randomized and treated in the late-breaking abstract

> “1272 pts were randomized and treated in ABTECT‐1 (636) and ABTECT‐2 (636).”

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

<a id="heading-3.1.2.7.2"></a>

#### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

##### Analysis population in the posted results

> “Overall Number of Baseline Participants 318 159 159 636 [Not Specified] Baseline Analysis Population Description”

Source: [ClinicalTrials.gov NCT05507216 results](https://clinicaltrials.gov/study/NCT05507216?tab=results)

<a id="topic-3.1.2.7.2-2"></a>

##### Analysis sets in the statistical analysis plan

> “The Randomized Set includes all subjects who were randomized to study treatment. The FAS includes all randomized subjects who received at least one dose of study drug. Subjects will be analyzed according to the treatment group to which they were randomized (i.e., “as randomized”), regardless of the treatment received. The efficacy analysis will be based on the FAS.”
> “The Safety Set includes all randomized subjects who have received at least one dose of study drug. Subjects will be analyzed according to the treatment received (i.e., “as treated”).”

Source: [Abivax ABX464-106 statistical analysis plan (2025)](https://cdn.clinicaltrials.gov/large-docs/16/NCT05507216/SAP_001.pdf)

<a id="topic-3.1.2.7.2-3"></a>

##### Primary analysis method, region factor, and testing sequence in the protocol

> “will be analyzed using a Cochran Mantel Haenszel test (CMH) test adjusting for AT-IR (yes/no), baseline oral corticosteroid treatment (yes/no) and Region (Japan/Rest of world) as stratification factors, using the Full Analysis Set (FAS).”
> “The Region (Japan/Rest of world) factor will not be included in the primary analysis model for consistency with ABX464-105 but may be included in a sensitivity analysis.”
> “If comparisons on primary endpoints for each dose are statistically significant, then, the testing procedure will continue through each of the key secondary endpoints in the prespecified order until an endpoint fails to reach statistical significance, after which all subsequent key secondary endpoints will be considered exploratory.”
> “Interim analysis: No interim analysis is planned.”

Source: [Abivax ABX464-106 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/16/NCT05507216/Prot_000.pdf)

<a id="topic-3.1.2.7.2-4"></a>

##### Handling of intercurrent events and missing data in the statistical analysis plan

> “The Composite Strategy will be applied for each of the above IEs for the main analyses of all primary and key secondary estimands.”
> “In the main analysis of all binary responder-type endpoints, subjects with missing data, regardless of reason for missingness, will be considered as non-responders.”

Source: [Abivax ABX464-106 statistical analysis plan (2025)](https://cdn.clinicaltrials.gov/large-docs/16/NCT05507216/SAP_001.pdf)

<a id="topic-3.1.2.7.2-5"></a>

##### Consequence of the 25 mg primary endpoint result for the testing hierarchy

> “Hierarchical testing strategy was used starting with 50 mg for the primary endpoint followed by the key secondary endpoints; the 25 mg was subsequently tested for the primary endpoint followed by the key secondary endpoints.”
> “25 mg did not meet the primary endpoint at week 8 in ABTECT‐2 in the FDA testing protocol, therefore p ‐values for key secondary endpoints for the 25 mg arm in ABTECT‐2 are nominal.”

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

<a id="heading-3.1.2.8"></a>

### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

#### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

##### Participant flow by arm in the posted results

| Disposition | ABX464 50 mg | ABX464 25 mg | Placebo |
| --- | --- | --- | --- |
| Started | “318” | “159” | “159” |
| Completed | “291” | “142” | “145” |
| Not completed | “27” | “17” | “14” |
| Adverse event | “13” | “8” | “8” |
| Lack of efficacy | “2” | “2” | “1” |
| Lost to follow-up | “3” | “0” | “0” |
| Protocol violation | “0” | “1” | “2” |
| Withdrawal by subject | “9” | “6” | “3” |

Source: [ClinicalTrials.gov NCT05507216 results](https://clinicaltrials.gov/study/NCT05507216?tab=results)

<a id="heading-3.1.2.8.2"></a>

#### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

##### Baseline characteristics by arm in the posted results

| Characteristic | ABX464 50 mg (n=318) | ABX464 25 mg (n=159) | Placebo (n=159) | Total (n=636) |
| --- | --- | --- | --- | --- |
| Age, years, mean (SD) | “41.4(13.64)” | “41.3(12.83)” | “41.6(14.68)” | “41.4(13.69)” |
| Age 65 years or older, participants | “19” | “6” | “16” | “41” |
| Female, participants | “138” | “60” | “58” | “256” |
| Male, participants | “180” | “99” | “101” | “380” |
| Asian, participants | “66” | “29” | “39” | “134” |
| Black or African American, participants | “6” | “3” | “4” | “13” |
| White, participants | “231” | “116” | “108” | “455” |
| Weight, kg, mean (SD) | “71.75(17.101)” | “73.37(16.050)” | “73.91(17.387)” | “72.69(16.919)” |
| Duration of ulcerative colitis, years, mean (SD) | “7.74(7.193)” | “7.92(6.769)” | “7.75(6.503)” | “7.79(6.911)” |
| At least one prior advanced therapy inadequate response, participants | “159” | “76” | “79” | “314” |
| Inadequate response to JAK inhibitors among those with AT-IR, participants | “33” | “19” | “20” | “72” |
| Modified Mayo Score, mean (SD) | “6.9(1.11)” | “7.0(1.04)” | “6.8(0.98)” | “6.9(1.06)” |
| Mayo endoscopic subscore 2, participants | “130” | “56” | “64” | “250” |
| Mayo endoscopic subscore 3, participants | “188” | “103” | “95” | “386” |
| Fecal calprotectin, µg/g, mean (SD) | “3759.05(7548.48)” | “4121.86(7081.92)” | “4499.81(8074.99)” | “4038.06(7569.95)” |

Source: [ClinicalTrials.gov NCT05507216 results](https://clinicaltrials.gov/study/NCT05507216?tab=results)

<a id="topic-3.1.2.8.2-2"></a>

##### Disease severity of the 25 mg group compared with ABTECT-1 stated by the company

> “In both trials, baseline demographics and disease characteristics were similar between groups; 45% and 49% of patients had inadequate response to one or more advanced therapies.”
> “A slightly more severe and refractory population were randomized to the 25 mg group in ABTECT-2 compared to ABTECT-1.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="topic-3.1.2.8.2-3"></a>

##### Proportion with prior advanced therapy inadequate response in the late-breaking abstract

> “Among pts who participated in ABTECT‐1, ABTECT‐2, and the pooled analysis, 45.3% (288/636), 49.4% (314/636), and 47.3% (602/1272) were AT‐IR‐Yes, respectively; 54.7% (348/636), 50.6% (322/636), 52.7% (670/1272) were AT‐IR‐No.”

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

<a id="heading-3.1.2.8.3"></a>

#### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

##### Primary and key secondary endpoints at Week 8

| Endpoint at Week 8, % (n) | Placebo (N=159) | Obefazimod 25 mg (N=159) | Obefazimod 50 mg (N=318) | 25 mg minus placebo, % | 25 mg p-value | 50 mg minus placebo, % | 50 mg p-value |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Clinical remission (primary) | “6.3 (10)” | “11.3 (18)” | “19.8 (63)” | “5.1” | “p = 0.1034” | “13.4” | “p = 0.0001” |
| Clinical response | “33.3 (53)” | “53.5 (85)” | “63.2 (201)” | “20.1” | “p = 0.0002” | “29.6” | “p < 0.0001” |
| Endoscopic improvement | “10.1 (16)” | “22.0 (35)” | “35.5 (113)” | “12.0” | “p = 0.0029” | “25.4” | “p < 0.0001” |
| HEMI | “7.5 (12)” | “13.2 (21)” | “23.9 (76)” | “5.7” | “p = 0.0932” | “16.4” | “p < 0.0001” |
| Symptomatic remission | “22.0 (35)” | “33.3 (53)” | “40.3 (128)” | “11.4” | “p = 0.0227” | “18.0” | “p < 0.0001” |

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

> “25 mg did not meet the primary endpoint at week 8 in ABTECT‐2 in the FDA testing protocol, therefore p ‐values for key secondary endpoints for the 25 mg arm in ABTECT‐2 are nominal.”
> “Endoscopic improvement/symptomatic remission were co‐primary endpoints for the EMA protocol and were met by both doses in both trials.”

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

<a id="topic-3.1.2.8.3-2"></a>

##### Participants meeting each endpoint at Week 8 in the posted results

| Endpoint at Week 8, participants | ABX464 50 mg (n=318) | ABX464 25 mg (n=159) | Placebo (n=159) |
| --- | --- | --- | --- |
| Clinical remission per modified Mayo Score (primary) | “63” | “18” | “10” |
| Endoscopic improvement | “113” | “35” | “16” |
| Clinical response per modified Mayo Score | “201” | “85” | “53” |
| HEMI per Geboes | “76” | “21” | “12” |

Source: [ClinicalTrials.gov NCT05507216 results](https://clinicaltrials.gov/study/NCT05507216?tab=results)

<a id="topic-3.1.2.8.3-3"></a>

##### Primary endpoint result for the 25 mg dose stated by the company

> “While the 25 mg dose did not achieve statistical significance for this endpoint in ABTECT-2, it achieved a pooled placebo-adjusted clinical response rate of 28.6%”

Source: [Abivax press release, ABTECT induction results (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-phase-3-results-both-abtect-8-week)

<a id="topic-3.1.2.8.3-4"></a>

##### Subgroups by prior advanced therapy inadequate response at Week 8 (nominal p-values)

| Endpoint at Week 8, % (n) | AT-IR-Yes placebo (N=79) | AT-IR-Yes 25 mg (N=76) | AT-IR-Yes 50 mg (N=159) | AT-IR-No placebo (N=80) | AT-IR-No 25 mg (N=83) | AT-IR-No 50 mg (N=159) |
| --- | --- | --- | --- | --- | --- | --- |
| Clinical remission | “5.1 (4)” | “5.3 (4)” | “12.6 (20)” | “7.5 (6)” | “16.9 (14)” | “27.0 (43)” |
| Endoscopic improvement | “8.9 (7)” | “11.8 (9)” | “26.4 (42)” | “11.3 (9)” | “31.3 (26)” | “44.7 (71)” |
| Symptomatic remission | “15.2 (12)” | “26.3 (20)” | “37.1 (59)” | “28.8 (23)” | “39.8 (33)” | “43.4 (69)” |
| HEMI | “6.3 (5)” | “7.9 (6)” | “17.0 (27)” | “8.8 (7)” | “18.1 (15)” | “30.8 (49)” |
| Clinical response | “20.3 (16)” | “40.8 (31)” | “57.2 (91)” | “46.3 (37)” | “65.1 (54)” | “69.2 (110)” |

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

| Placebo-adjusted difference at Week 8, % and nominal p-value | AT-IR-Yes 25 mg | AT-IR-Yes 50 mg | AT-IR-No 25 mg | AT-IR-No 50 mg |
| --- | --- | --- | --- | --- |
| Clinical remission | “0.7 p = 0.8529” | “7.6 p = 0.0652” | “9.5 p = 0.0659” | “19.4 p = 0.0004” |
| Endoscopic improvement | “3.5 p = 0.4675” | “17.7 p = 0.0015” | “20.3 p = 0.0016” | “33.1 p < 0.0001” |
| Symptomatic remission | “11.3 p = 0.0841” | “21.7 p = 0.0006” | “11.0 p = 0.1430” | “14.2 p = 0.0329” |
| HEMI | “1.8 p = 0.6596” | “11.0 p = 0.0197” | “9.3 p = 0.0805” | “21.8 p = 0.0002” |
| Clinical response | “21.0 p = 0.0043” | “36.8 p < 0.0001” | “18.8 p = 0.0165” | “22.2 p = 0.0008” |

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

<a id="heading-3.1.2.8.4"></a>

#### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.2.8.5"></a>

#### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

##### Treatment-emergent adverse events at Week 8 reported by the company

| Event, n (%) | Placebo (N=159) | Obefazimod 25 mg (N=159) | Obefazimod 50 mg (N=318) |
| --- | --- | --- | --- |
| Any TEAE | “77 (48.4%)” | “81 (50.9%)” | “194 (61.0%)” |
| TEAE leading to study drug discontinuation | “9 (5.7%)” | “8 (5.0%)” | “15 (4.7%)” |
| Serious TEAE | “7 (4.4%)” | “6 (3.8%)” | “6 (1.9%)” |
| Malignancy | “0 (0.0%)” | “0 (0.0%)” | “0 (0.0%)” |
| Serious or severe (grade 3 or higher) infections and opportunistic infections | “0 (0.0%)” | “0 (0.0%)” | “2 (0.6%)” |

Source: [Abivax press release, ABTECT induction results (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-phase-3-results-both-abtect-8-week)

<a id="topic-3.1.2.8.5-2"></a>

##### Serious adverse events, all-cause mortality, and adverse event time frame in the posted results

| Event, affected/at risk (%) | ABX464 50 mg | ABX464 25 mg | Placebo |
| --- | --- | --- | --- |
| All-cause mortality | “0/318 (0.00%)” | “0/159 (0.00%)” | “0/159 (0.00%)” |
| Any serious adverse event | “6/318 (1.89%)” | “6/159 (3.77%)” | “7/159 (4.40%)” |
| Colitis ulcerative | “2/318 (0.63%)” | “2/159 (1.26%)” | “3/159 (1.89%)” |
| Pancreatitis acute | “0/318 (0.00%)” | “1/159 (0.63%)” | “1/159 (0.63%)” |
| Pneumonia | “1/318 (0.31%)” | “0/159 (0.00%)” | “0/159 (0.00%)” |
| Uveitis | “0/318 (0.00%)” | “1/159 (0.63%)” | “0/159 (0.00%)” |
| Lipase increased | “0/318 (0.00%)” | “1/159 (0.63%)” | “0/159 (0.00%)” |
| Acute coronary syndrome | “0/318 (0.00%)” | “0/159 (0.00%)” | “1/159 (0.63%)” |

Source: [ClinicalTrials.gov NCT05507216 results](https://clinicaltrials.gov/study/NCT05507216?tab=results)

> “Adverse Events Time Frame Up to 12 weeks”
> “Adverse events reported here are treatment emergent adverse events.”

Source: [ClinicalTrials.gov NCT05507216 results](https://clinicaltrials.gov/study/NCT05507216?tab=results)

<a id="topic-3.1.2.8.5-3"></a>

##### Non-serious adverse events at a 5% reporting threshold in the posted results

| Event, affected/at risk (%) | ABX464 50 mg | ABX464 25 mg | Placebo |
| --- | --- | --- | --- |
| Any non-serious adverse event at 5% threshold | “115/318 (36.16%)” | “40/159 (25.16%)” | “32/159 (20.13%)” |
| Headache | “82/318 (25.79%)” | “23/159 (14.47%)” | “9/159 (5.66%)” |
| Nausea | “29/318 (9.12%)” | “11/159 (6.92%)” | “3/159 (1.89%)” |
| Lipase increased | “19/318 (5.97%)” | “2/159 (1.26%)” | “4/159 (2.52%)” |
| N-terminal prohormone brain natriuretic peptide increased | “7/318 (2.20%)” | “3/159 (1.89%)” | “11/159 (6.92%)” |
| Anaemia | “12/318 (3.77%)” | “6/159 (3.77%)” | “11/159 (6.92%)” |

Source: [ClinicalTrials.gov NCT05507216 results](https://clinicaltrials.gov/study/NCT05507216?tab=results)

<a id="topic-3.1.2.8.5-4"></a>

##### Adverse events in the late-breaking abstract

> “For ABTECT2, TEAEs occurred in 61.0%, 50.9%, and 48.4% for Obe‐50, Obe‐25, and PBO, respectively.”
> “The overall rate of serious adverse events and treatment emergent adverse events (TEAEs) leading to study drug discontinuation for pts treated with Obe were similar to PBO.”

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

<a id="heading-3.1.2.9"></a>

### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

#### Summary: study limitations

- Duration and comparator: ABTECT-2 compared obefazimod 25 mg and 50 mg once daily with placebo for 8 weeks, with adverse events collected for up to 12 weeks, and has no active comparator. Durability is assessed only in the separate ABTECT Maintenance trial. The pooled ABTECT-1 and ABTECT-2 analyses, including all patient-reported outcome results, are recorded under ABTECT-1; no patient-reported outcome result specific to ABTECT-2 was identified.
- Primary endpoint by dose: the 50 mg dose met the primary endpoint (clinical remission 19.8% against 6.3% with placebo; difference 13.4%, p=0.0001). The 25 mg dose did not (11.3% against 6.3%; difference 5.1%, p=0.1034), so under the hierarchical testing scheme the p-values for its key secondary endpoints are nominal. The company states that a “slightly more severe and refractory population” was randomized to 25 mg in ABTECT-2 than in ABTECT-1; in the posted baseline data, 76 of 159 participants receiving 25 mg had a prior advanced therapy inadequate response and 103 had a Mayo endoscopic subscore of 3.
- Sources of the results: the results come from the ClinicalTrials.gov posting (first posted September 10, 2026), a congress abstract, and company press releases and filings. The posted results do not specify the analysis population for baseline characteristics or outcome measures.
- Population: participants were 16 years or older (18 or older in the EU, the EEA, Israel, Serbia, and Ukraine) with a modified Mayo Score of 5 or more and a centrally read endoscopic subscore of 2 or 3. Of 636 participants, 314 (49.4%) had a prior advanced therapy inadequate response and 72 had a prior inadequate response to a JAK inhibitor; 41 were 65 years or older and 13 were Black or African American. Randomization was also stratified by region (Japan or rest of world), and the registry lists 262 locations. The protocol excludes the region factor from the primary analysis model “for consistency with ABX464-105”.
- Background therapy: stable oral 5-ASA and oral corticosteroids were allowed in all arms, and the protocol states that such therapy “may be partially effective at controlling UC symptoms”.
- Subgroups: subgroup results by prior advanced therapy inadequate response come from small groups. Among participants with a prior inadequate response, clinical remission occurred in 4 of 76 (5.3%) receiving 25 mg and 4 of 79 (5.1%) receiving placebo (p=0.8529), and in 20 of 159 (12.6%) receiving 50 mg (p=0.0652).
- Safety reporting: serious adverse events occurred in 6 of 318 participants (1.89%) receiving 50 mg, 6 of 159 (3.77%) receiving 25 mg, and 7 of 159 (4.40%) receiving placebo. Non-serious lipase increase was reported in 19 of 318 (5.97%) receiving 50 mg and 4 of 159 (2.52%) receiving placebo, and serious acute pancreatitis in 1 participant receiving 25 mg and 1 receiving placebo.

Source: [ClinicalTrials.gov NCT05507216](https://clinicaltrials.gov/study/NCT05507216); [ClinicalTrials.gov NCT05507216 results](https://clinicaltrials.gov/study/NCT05507216?tab=results); [Abivax ABX464-106 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/16/NCT05507216/Prot_000.pdf); [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/); [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
